Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Investor Presentation (March 2022)
28 slides from Valiant Organics's investor presentation, March 2022
Slide 1: Investor Presentation | March 2022
Investor Presentation | March - 2022
Slide 2: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisdine and Para Anisidne Diversified client base across Amongst 1st few
Slide 3: Company Overview
eeee Valiant O1 9000 COMPANY OVERVIEW
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Board of Directors
Board of Directors Shri Velji K. Gogri – Chairman, Independent Director Shri Bijal D. Modi – Executive Director Chemical Engineer having 37 years of experience in the chemical industry, graduated Chemical Engineer from Mumbai University. He is managing Jhagadia plant since from IIT Mumbai. A number
Slide 6: Key Milestones
Key Milestones Expanded product range to Listed on BSE Main Board; include Chlorophenols, for Commenced Ammonolysis Received Environmental usage in intermediates in expansion at Vapi unit; clearance to enhance Pharmaceuticals, Commenced Converted into Limited Completed backward Chlorophenol capacity
Slide 7: Marquee Clientele
Marquee Clientele Shiv Corporation SALTIGO GmbH Anupam Rasayan Lanxess India Aarti Industries (Prop-Jenil (Lanxess Group) India Ltd. Private Limited Enterprise Pvt. Ltd.) Clariant Chemicals Spectrum Dyes & Supreet Chemical Kumar Organic Kisco Ltd. (India) Ltd. Chemicals Pvt. Ltd. Pvt. Ltd. Products
Slide 8: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 27,000 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 9: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 10: Capex Projects
Capex Projects Approx Capex Product Installed Capacity Project Status Remarks (INR Mn) Commissioned Para Nitro Aniline (PNA) & Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Ortho Chloro Para Nitro 550 ~ 70 • Full capacity addition in progress Aniline (OCPNA) Ortho Nitro Ani
Slide 11: Business Overview
seco Valiant Organics Limited 9000 BUSINESS OVERVIEW
Slide 12: Chemistries And Product Basket
Chemistries And Product Basket Ammonolysis Chlorination Key Products: Industries Served: 36% Key Products: Industries Served: • Para Nitro Aniline • Dyes • Para ChloroPhenol (PCP) • Agro Chemicals • Ortho Chloro Para Nitro Aniline • Pigments • Ortho ChloroPhenol (OCP) • Cosmetics • 2,4 Di Chlorophen
Slide 13: Chlorination
Chlorination Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired Revenues (INR Mn)* outcome is known as chlorination. 2, 250 2,195 • Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market 2,
Slide 14: Ammonolysis
Ammonolysis Ammonolysis is a high-pressure chemical reaction done in an auto clave where ammonia is used as a reactant. Revenues (INR Mn)* • Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. 2, 500 2,136 2,093 in 2017 & Amarjyot Chemica
Slide 15: Hydrogenation
Hydrogenation Hydrogenation is a chemical reaction between molecular hydrogen (H2) and another compound or element, usually in the presence of a catalyst. Revenues (INR Mn)* • The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) 2, 000 1,900 h
Slide 16: Other Processes
Other Processes Acetylation Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound. Revenues (INR Mn)* • The acetylation procedure is carried out at the company’s Ahmedabad facility which has a capacity of 1,800 700 605 567 565 MTPA 600 500 462 • The
Slide 17: Industry Overview
seco Valiant Organics Limited 9000 INDUSTRY OVERVIEW
Slide 18: Industry Overview
Industry Overview • The chemicals industry in India covers more than 80,000 commercial products. Global Chemical Market (USD Bn) Commodi ty Chemicals 8, 000 Speci alty Chemi cals • India is 6th largest manufacturer of chemicals in the world and 4th largest in Asia. 7, 000 910 6, 000 Others 435 1090
Slide 19: Advantage India: Key Growth Factors
Key Growth Factors GROWING OPPORTUNITIES POLICY INCREASING ADVANTAGE INDIA DEMAND SUPPORT INVESTMENT • Rise in demand from end-users • Supply disruption in China has • The government plans to Industries such as food processing, caused the global end-user • India’s specialty chemical introduce produc
Slide 20: Financial Overview
seco Valiant Organics Limited 9000 FINANCIAL OVERVIEW
Slide 21: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY19 FY20 FY21* 9M-FY22* Operational Income 6,923 6,749 7,548 8,056 Total Expenses 5,125 4,946 5,496 6,578 EBITDA 1,798 1,803 2,052 1,478 EBITDA Margin 25.97% 26.71% 27.19% 18.35% Other Income 87 63 59 52 Depreciation 136 158 212 212 Fina
Slide 22: Consolidated Balance Sheet
Consolidated Balance Sheet Particulars (INR Mn) FY20 FY21* H1-FY22* Particulars (INR Mn) FY20 FY21* H1-FY22* EQUITY 4,007 5,086 5,603 Non-Current Assets 4,451 5,729 6,327 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,729 4,967 5,094 b) Other Equity 3,736 4,747 5,253 b) Capit
Slide 23: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY19 FY20 FY21* 9M-FY22* Revenue from Operations 6,060 5,836 5,742 6,579 Total Expenses 4,283 4,103 4,170 5,373 EBITDA 1,777 1,733 1,572 1,206 EBITDA Margin 29.32% 29.69% 27.37% 18.33% Other Income 64 52 169 46 Depreciation 118 130 186 200
Slide 24: Standalone Balance Sheet
Standalone Balance Sheet Particulars (INR Mn) FY20 FY21* H1-FY22* Particulars (INR Mn) FY20 FY21* H1-FY22* EQUITY 3,875 5,023 5,488 Non-Current Assets 4,381 5,797 6,506 a) Equity Share Capital 121 272 272 a) Property, Plant and Equipment 2,525 4,771 4,901 b) Capital Work In Progress 1,291 459 932 b)
Slide 25: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn)* EBITDA (INR Mn) & EBITDA Margins (%) * PAT (INR Mn) & PAT Margins (%) * 8, 500 2,300 80.00% 1,332 1, 500 80. 00% 2,052 1,282 1,309 8,056 70.00% 2,000 70. 00% 8, 000 1,798 1,803 60.00% 1, 200 7,548 60. 00% 1,700 908 7, 500 1,478 50.00% 9
Slide 26: Capital Market Information
Capital Market Information Share Price as of 31st December, 2021 40% 20% 0% -20% -40% Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 VALIANT Sensex Price Data (31st December, 2021) INR Shareholding pattern as of 31st December, 2021 Face Value 10.00 Market Price 1
Slide 27: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 28: Thank You
eeee Valiant O1 9000 THANK YOU
Valiant Organics — Investor Presentation (March 2022) on 6ix